Characteristics of recipients of tixagevimab-cilgavimab (T/C) who developed COVID-19 infection between December 19, 2021 and July 31, 2022 when Omicron was the dominant circulating variant.
收藏NIAID Data Ecosystem2026-05-01 收录
下载链接：
https://figshare.com/articles/dataset/Characteristics_of_recipients_of_tixagevimab-cilgavimab_T_C_who_developed_COVID-19_infection_between_December_19_2021_and_July_31_2022_when_Omicron_was_the_dominant_circulating_variant_/22712346
下载链接
链接失效反馈官方服务：
资源简介：
Characteristics of T/C recipients who were infected prior to receiving T/C (pre-T/C) are compared with characteristics of T/C recipients who were diagnosed with COVID after having received any dose of T/C (post-T/C).
创建时间：
2023-04-27
